Atrial Fibrillation Guidelines Updated

Published Online: Thursday, April 10, 2014
Follow Pharmacy_Times:
The American Heart Association, American College of Cardiology, and Heart Rhythm Society have updated their guidelines on management of atrial fibrillation. The new guidelines include recommendations regarding use of new oral anticoagulants—dabigatran, rivaroxaban, and apixaban—as well as warfarin. However, the guidelines do not specify preferences among the 3 new oral anticoagulants due to a lack of head-to-head trials and note that treatment decisions should be based on concerns including risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics. The guidelines will be published in the Journal of the American College of Cardiology, Circulation, Journal of the American Heart Association, and Heart Rhythm.

To read more about the new guidelines on HCPLive, click here.
Related Articles
Heart Hospital of New Mexico at Lovelace Medical Center has received the Mission: Lifeline Gold Receiving Quality Achievement Award.
A practice-changing study suggests bridging anticoagulation does more harm than good in atrial fibrillation (AF) patients treated with warfarin.
Studies have reported that up to half of patients discontinue prescribed therapies soon after hospital discharge.
New study results suggest idarucizumab is an effective reversal agent for Boehringer Ingelheim's novel oral anticoagulant (NOAC), dabigatran (Pradaxa).
Latest Issues
$auto_registration$